|Author(s)/Faculty: Joyce L. Ross, MSN, ANP, CRNP, CLS, FNLA; Dave L. Dixon, PharmD, BCPS, CDE, FNLA; Dean A. Bramlet, MD, FNLA; Daniel J. Rader, MD, FNLA; Joseph J. Saseen, PharmD, CLS, FNLA|
With each passing year we gain new insight and understanding around the clinical utilization of lipid-lowering therapeutic agents. Our historical experience with older agents can often inform our knowledge and interpretation of how we view newly available options and those in development.
How does our prior experience with statins and LDL-C lowering help us to better utilize and contextualize the newest classes of specialized high-intensity therapies? When do we consider off-label drug use in patient populations without outcomes data? Where is the future of individualized risk management headed? These are the some of the questions our expert-presenters addressed with a live audience in Philadelphia.
Join us on LipidCME to view the interactive session and earn free CME/CE credits.